Tobramycin Administered by eFlow Rapid Nebulizer: Pharmacokinetic Study
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study assesses the aerosol delivery characteristics (measured by nebulization time,
serum and sputum tobramycin pharmacokinetic parameters) and safety of tobramycin administered
for inhalation by PARI eFlow rapid electronic nebulizer (no compressor) vs. PARI LC PLUS Jet
Nebulizer (with compressor) in subjects with cystic fibrosis.